Carfilzomib-associated renal toxicity is common and unpredictable: a comprehensive analysis of 114 multiple myeloma patients

[1]  K. Ohashi,et al.  Renal-Limited Thrombotic Microangiopathy due to Bevacizumab Therapy for Metastatic Colorectal Cancer: A Case Report , 2019, Case Reports in Oncology.

[2]  B. Lipe,et al.  Carfilzomib-induced aHUS responds to early eculizumab and may be associated with heterozygous CFHR3-CFHR1 deletion. , 2018, Blood advances.

[3]  M. Dimopoulos,et al.  Proteasome inhibitor associated thrombotic microangiopathy , 2016, American journal of hematology.

[4]  S. Vesely,et al.  Drug-induced thrombotic microangiopathy: a systematic review of published reports. , 2015, Blood.

[5]  Aspire Investigators,et al.  Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma , 2015 .

[6]  J. Velez,et al.  Renal thrombotic microangiopathy and podocytopathy associated with the use of carfilzomib in a patient with multiple myeloma , 2014, BMC Nephrology.

[7]  S. Seshan,et al.  Clinicopathological spectrum of kidney diseases in cancer patients treated with vascular endothelial growth factor inhibitors: a report of 5 cases and review of literature. , 2014, Human pathology.

[8]  J. George,et al.  Syndromes of thrombotic microangiopathy. , 2014, The New England journal of medicine.

[9]  S. Jagannath,et al.  Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies , 2013, Haematologica.

[10]  R. Vij,et al.  Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety , 2013, Leukemia.

[11]  G. Baumann,et al.  Proteasome inhibition prevents experimentally-induced endothelial dysfunction. , 2009, Life sciences.

[12]  C. Bartsch,et al.  Long‐term up‐regulation of eNOS and improvement of endothelial function by inhibition of the ubiquitin–proteasome pathway , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[13]  P. Camuto,et al.  A Report of 5 Cases and a Review of the Literature , 2017 .

[14]  H. Goldschmidt,et al.  Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. , 2016, The Lancet. Oncology.

[15]  K. Jhaveri,et al.  Carfilzomib-related acute kidney injury. , 2013, Clinical advances in hematology & oncology : H&O.

[16]  D. C. Henckel,et al.  Case report. , 1995, Journal.